Bilastine - Novel anti histamine drug for allergic rhinitis

---

Review Article

Author Details : Abhijit Trailokya*, Soumen Roy

Volume : 7, Issue : 1, Year : 2022

Article Page : 6-10

https://doi.org/10.18231/j.ijirm.2022.003

Suggest article by email

Get Permission

---

Abstract

The immune system is a fundamental part of human protection against infection and disease.The immune system can occasionally lead to unfavourable reactions in the host which are known as hypersensitivity reactions. The exaggerated immune reactivity (hypersensitivity) to certain environmental substances (allergens) like airborne pollens, dust, mites, pet dander, and reactions to certain foods that normally have little effect on most people is known as allergy. The incidence of allergic disease like allergic rhinitis (AR), food borne allergy, asthma and anaphylactic reactions are prevalent in 25% of populations predominately in adolescents and adults in industrialised countries. Bilastine is a novel second-generation non-sedative, highly selective histamine H1 receptor antagonist that suppresses some allergic inflammatory processes that inhibits the release of histamine from mast cells and is approved in the treatment allergic rhinitis, urticaria and pruritus associated with skin diseases. This review covers the safety, efficacy and pharmacological aspects of Bilastine as an important product for treatment of allergic rhinitis.
 

Keywords: Allergic rhinitis, Bilastine, Urticaria

How to cite : Trailokya A, Roy S, Bilastine - Novel anti histamine drug for allergic rhinitis. IP Indian J Immunol Respir Med 2022;7(1):6-10

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.